The first shipment of Johnson & Johnson vaccines has arrived in Poland

120,000 Johnson & Johnson vaccines arrived in Poland this morning. This information was confirmed in the Strategic Reserves Agency by RMF FM correspondent Michał Dobrołowicz.

The company yesterday announced the decision that It will delay the introduction of its preparation into the European Union market. Reason 6 cases of blood clots are rare in the United States – out of nearly 7 million people who have been vaccinated.

As identified by RMF FM correspondent Michał Dobrołowicz in Poland Johnson & Johnson vaccines will now be sent, as planned, to vaccination centers. When asked by a RMF FM journalist, when the first people in Poland will receive this setup, the answer is: “In the coming days.”

A Ministry of Health spokesperson explained to Michał Dobrołowicz that the European Medicines Agency had not changed its recommendation after the reports from the United States. A new contact may be issued by the agency today. For now, the green light for this vaccine is still on.

Poll: What should it look like to register to get vaccinated against Covid-19?

The vaccine, called Covid-19 Vaccine Janssen, is the fourth preparation approved in the European Union. Johnson & Johnson vaccine is the only vaccine that requires only one dose. The Pfizer / BioNTech, Moderna, and AstraZeneca vaccines are two doses.

The preparation, developed by Janssen Pharmaceutica NV, a company in the Johnson & Johnson pharmaceutical division, In Poland it will – as the government announced – be used, among other things, for people who cannot reach vaccination points on their own.

The Covid-19 Janssen vaccine is given to people over the age of 18 by injection into a muscle only, and the upper arm is the preferred location. According to the summary of product characteristics, Protection begins approximately 14 days after vaccination.

The vaccine causes the immune system to produce antibodies and specialized white blood cells to act against the virus, thus providing protection against Covid-19.

The preparation is dispensed in vials containing five 0.5 ml doses. The glass bottle contains a rubber stopper, an aluminum cap and a blue plastic cap.

The unopened vial is valid for two years when stored at -25 ° C to -15 ° C. Once removed from the freezer, the unopened vaccine can be stored in the refrigerator at 2 ° C to 8 ° C, protected from light, for a period of up to three months. In temperatures between 9 ° C and 25 ° C, the unopened Covid-19 Janssen vaccine remains stable for 12 hours.

After the vial is first punctured, the product can be stored at 2 ° C – 8 ° C for a maximum of 6 hours or left at room temperature (maximum 25 ° C) for up to 3 hours after opening.

The vaccine is based on the replica deficient Adenovirus, Ad26. It is the vector of genetic material through which the vaccinated person’s cells begin to produce the spike protein (spike protein, S protein) for the SARS-CoV-2 virus that causes Covid-19. By interacting with the protein of the virus, the body builds immunity.

People over the age of 57 can register for the vaccination starting today

The US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) recommended, yesterday, to stop vaccination with the preparation in the United States due to the occurrence of six rare cases of blood clots among the 6.8 million people who were vaccinated.

In light of the signals, the European Medicines Agency (EMA) last week began work on evaluating the thrombotic and thrombotic events reported in people who have received Janssen against Covid-19.

Previously, coagulopathy with thrombocytopenia also occurred in people vaccinated with AstraZeneka. In the end, after analyzing these cases, EMA gave an opinion in early April that these are very rare cases, and that AstraZeneki’s benefits in preventing Covid-19 outweigh the risks of side effects.

The European Union has applied for 200 million doses of the Johnson & Johnson vaccine with an option for an additional 200 million doses. In mid-March, the President of the European Commission, Ursula von der Leyen, announced that the European Union countries should receive in the second quarter of this year. Approximately 55 million doses of the preparation.

Leave a Reply

Your email address will not be published.